Patents by Inventor Richard J. Varsolona
Richard J. Varsolona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11542279Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.Type: GrantFiled: June 1, 2017Date of Patent: January 3, 2023Assignee: Merck Sharp & Dohme LLCInventors: Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
-
Publication number: 20220242866Abstract: The present invention provides processes for the preparation of 2-fluoroadenine, as well as certain intermediates useful in the preparation of 2?-deoxy-4?-C-ethynyl-2-fluoroadenosine (EFdA): EFdA.Type: ApplicationFiled: June 18, 2020Publication date: August 4, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: John Y.L. Chung, Cynthia Marilyn Hong, Guy R. Humphrey, Kevin M. Maloney, Yingju Xu, Richard J. Varsolona
-
Patent number: 11306080Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.Type: GrantFiled: June 8, 2018Date of Patent: April 19, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Laura M. Artino, William Morris, Eric Sirota, Richard J. Varsolona
-
Publication number: 20220056045Abstract: The instant invention is related to a novel solid form of ceftolozane sulfate (the DMAc solvate of ceftolozane sulfate (Form 3)), compositions comprising ceftolozane sulfate DMAc solvate (Form 3), synthesis of Form 3 and an improved crystallization process using Form 3 to prepare ceftolozane sulfate Form 2. Novel compositions also include ceftolozane sulfate solid Form 3 and/or other crystalline and amorphous solid forms of ceftolozane.Type: ApplicationFiled: June 1, 2017Publication date: February 24, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Kevin Matthew Maloney, Eric M. Sirota, Richard J. Varsolona, Donald R. Gauthier, Jr., Hong Ren
-
Publication number: 20220024902Abstract: The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.Type: ApplicationFiled: December 12, 2019Publication date: January 27, 2022Applicant: Intervet Inc.Inventors: Christophe Pierre Alain Chassaing, Xiaoling Jin, Rositza Iordanova Petrova, Richard J. Varsolona, Lorenzo Codan, Edward Cleator, Adrian Goodyear, Jonathan Simmons, Tanja Schweisel
-
Publication number: 20200199117Abstract: The present invention provides a novel crystalline form of verubecestat (Crystalline Form II of Verubecestat) and pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease and mild cognitive impairment, are disclosed herein.Type: ApplicationFiled: June 8, 2018Publication date: June 25, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Laura M. Artino, William Morris, Eric Sirota, Richard J. Varsolona
-
Patent number: 10457690Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.Type: GrantFiled: June 3, 2016Date of Patent: October 29, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
-
Publication number: 20180179223Abstract: The present invention is directed to processes for preparing Substituted Tetracyclic Heterocycle Compounds of formula (I): (I) which may be useful as HCV NS5A inhibitors. The present invention is also directed to compounds that may be useful as synthetic intermediates and catalysts in the processes of the invention.Type: ApplicationFiled: June 3, 2016Publication date: June 28, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Jingjun Yin, Tetsuji Itoh, Jianguo Yin, Bangping Xiang, Kevin R. Campos, Alexei Kalinin, Zhuqing Liu, Melodie Deniz Christensen, Kevin M. Belyk, Richard J. Varsolona, Andrew Brunskill
-
Publication number: 20140057928Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: ApplicationFiled: October 30, 2013Publication date: February 27, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rolf-Stefan BRICKL, Shirlynn CHEN, Jihchin CHUNG, Mayur Suryakant DUDHEDIA, Danping LI, Zhi-Hui LU, Siddharthya MUJUMDAR, Chitra TELANG, Richard J. VARSOLONA, Zeren WANG
-
Patent number: 8598183Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: GrantFiled: September 23, 2011Date of Patent: December 3, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Rolf-Stefan Brickl, Shirlynn Chen, Jihchin Chung, Mayur Suryakant Dudhedia, Danping Li, Zhi-Hui Lu, Siddharthya Mujumdar, Chitra Telang, Richard J. Varsolona, Zeren Wang
-
Patent number: 8362035Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: GrantFiled: July 3, 2012Date of Patent: January 29, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
-
Publication number: 20120270775Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
-
Patent number: 8232293Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: GrantFiled: September 15, 2009Date of Patent: July 31, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
-
Publication number: 20120122887Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: ApplicationFiled: September 23, 2011Publication date: May 17, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rolf-Stefan BRICKL, Shirlynn CHEN, Jihchin CHUNG, Mayur Suryakant DUDHEDIA, Danping LI, Zhi-Hui LU, Siddharthya MUJUMDAR, Chitra TELANG, Richard J. VARSOLONA, Zeren WANG
-
Publication number: 20100093792Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: ApplicationFiled: September 15, 2009Publication date: April 15, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
-
Publication number: 20090088571Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.Type: ApplicationFiled: December 5, 2008Publication date: April 2, 2009Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.Inventors: Xiao-jun WANG, Thomas WIRTH, Thomas NICOLA, Li ZHANG, Rogelio Perez FRUTOS, Yibo XU, Dhileepkumar KRISHNAMURTHY, Laurence John NUMMY, Richard J. VARSOLONA, Chris Hugh SENANAYAKE, Jutta KROEBER, Diana REEVES
-
Patent number: 7470795Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.Type: GrantFiled: July 25, 2005Date of Patent: December 30, 2008Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbHInventors: Xiao-jun Wang, Thomas Wirth, Thomas Nicola, Li Zhang, Rogelio Perez Frutos, Yibo Xu, Dhileepkumar Krishnamurthy, Laurence John Nummy, Richard J. Varsolona, Chris Hugh Senanayake, Jutta Kroeber, Diana Reeves
-
Publication number: 20040229777Abstract: This invention relates to novel crystalline phases of the following Compound (1), methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 1Type: ApplicationFiled: March 25, 2004Publication date: November 18, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Michael Kenneth Cerreta, John Andrew Smoliga, Richard J. Varsolona
-
Patent number: 6642237Abstract: &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.Type: GrantFiled: November 21, 2000Date of Patent: November 4, 2003Assignee: Merck & Co., Inc.Inventors: James R. Tata, Kevin T. Chapman, Joseph Leslie Duffy, Nancy J. Kevin, Yuan Cheng, Thomas A. Rano, Fengqi Zhang, Tracy Huening, Brian Anthony Kirk, Zhijian Lu, Subharekha Raghavan, Fred J. Fleitz, Daniel E. Petrillo, Joseph D. Armstrong, III, Richard J. Varsolona, David Askin, R. Scott Hoerrner, Robert Purick
-
Publication number: 20030176501Abstract: The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.Type: ApplicationFiled: November 13, 2002Publication date: September 18, 2003Inventors: Richard D. Tillyer, Paul J. Reider, Edward J. J. Grabowski, Feng Xu, Robert M. Wenslow, Jose M. Vega, Richard J. Varsolona